Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Glenmark Pharmaceuticals Inc.
Current Parent Company: Glenmark Pharmaceuticals
Penalty: $25,000,000
Year: 2024
Date: September 4, 2024
Offense Group: government-contracting-related offenses
Primary Offense: False Claims Act and related
Secondary Offense: price-fixing or anti-competitive practices
Mega-Scandal: Price Fixing
Violation Description: A generic pharmaceutical manufacturer, Glenmark Pharmaceuticals Inc. USA, located in Mahwah, New Jersey, agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug. The government alleged that, between 2013 and 2015, Glenmark paid and received compensation prohibited by the Anti-Kickback Statute through arrangements on price, supply and allocation of customers with other pharmaceutical manufacturers for a generic drug manufactured by Glenmark, pravastatin, which is widely used to treat high cholesterol and triglyceride levels.
Level of Government: federal
Action Type: agency action
Agency: Justice Department Civil Division
Civil or Criminal Case: civil
HQ Country of Current Parent: India
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: generic pharmaceuticals
Source of Data: (click here)
Archived Source: (click here)
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.